Prostate cancer

News

Clovis hopes to get ahead of rivals in prostate cancer with ...

Clovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year's ESMO conference, as the company hopes to steal a march on AstraZeneca an

News

FDA says Clovis' Rubraca could be prostate cancer breakthrou...

Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.

News

Radiology technician examens mammography test on location

UK biotech Azeria pioneers research into cancer target FOXA1

A new UK biotech, Azeria Therapeutics has started on a mission to develop breakthrough treatments for drug-resistant breast and prostate cancer, based around a new target known as FOXA1.

News

Prostate drug approved for use in non-metastatic cases

The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic prostate cancer.

News

J&J gets quick approval for new next-gen prostate cancer dru...

The FDA has approved Johnson & Johnson’s next generation prostate cancer drug, apalutamide in an early but tough to treat form of prostate cancer that has not spread.

News